\
&
Contact us
This was 2 weeks ago
LocationHybrid (Brussels)
ProgrammesOrganised by the NGI Commons consortium in collaboration with the European Commission, the summit will feature discussions on scaling Digital Commons, funding mechanisms for sustainability, and the integration of the Open Internet Stack. Participants will hear from key stakeholders and engage in discussions designed to create a unified narrative for Digital Commons across Europe.
Attendees will explore the NGI Commons roadmap, discuss public procurement's role in Digital Commons, and elevate practitioner perspectives through case studies and analysis. The event will be conducted in-person, with online access available for remote participants.
Registration is free but mandatory, with limited in-person attendance. A detailed agenda and registration details can be found on the event website (also for online attendance).
The event is addressed to policymakers, regulators, funders & foundations, digital leaders from cities, industry and research and open source and commons practitioners
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health AI Continent Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.